These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 9757491)

  • 21. Docosahexaenoic acid enhances the susceptibility of human colorectal cancer cells to 5-fluorouracil.
    Calviello G; Di Nicuolo F; Serini S; Piccioni E; Boninsegna A; Maggiano N; Ranelletti FO; Palozza P
    Cancer Chemother Pharmacol; 2005 Jan; 55(1):12-20. PubMed ID: 15365767
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Interferons as biomodulators of fluoropyrimidines in the treatment of colorectal cancer.
    Makower D; Wadler S
    Semin Oncol; 1999 Dec; 26(6):663-71. PubMed ID: 10606259
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dihydropyrimidine dehydrogenase but not thymidylate synthase expression is associated with resistance to 5-fluorouracil in colorectal cancer.
    Nita ME; Tominaga O; Nagawa H; Tsuruo T; Muto T
    Hepatogastroenterology; 1998; 45(24):2117-22. PubMed ID: 9951876
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Chronotherapy with high dose carboplatin, 5-fluorouracil and leucovorin in advanced colorectal carcinoma].
    Popov I; Jelić S; Radosavljević D; Nikolić-Tomasević A
    Srp Arh Celok Lek; 1998; 126(9-10):355-61. PubMed ID: 9863407
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 5-FU split dose; a phase I/II and pharmacokinetic study of a different schedule of the Nordic regimen in advanced colorectal carcinoma.
    Berglund A; Carlsson G; Gustavsson B; Frödin JE; Ragnhammar P; Glimelius B
    Anticancer Res; 2003; 23(2C):1789-94. PubMed ID: 12820460
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy.
    Lecomte T; Ferraz JM; Zinzindohoué F; Loriot MA; Tregouet DA; Landi B; Berger A; Cugnenc PH; Jian R; Beaune P; Laurent-Puig P
    Clin Cancer Res; 2004 Sep; 10(17):5880-8. PubMed ID: 15355920
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects on DNA and RNA after the administration of two different schedules of 5-fluorouracil in colorectal cancer patients.
    Hoshino S; Yamashita Y; Maekawa T; Shirakusa T
    Cancer Chemother Pharmacol; 2005 Dec; 56(6):648-52. PubMed ID: 15959779
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dihydropyrimidine dehydrogenase deficiency: impact of pharmacogenetics on 5-fluorouracil therapy.
    Lee A; Ezzeldin H; Fourie J; Diasio R
    Clin Adv Hematol Oncol; 2004 Aug; 2(8):527-32. PubMed ID: 16163233
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Use of 5-fluorouracil in digestive cancer].
    Setiz JF; Perrier H; Giovannini M; Thill L
    Gastroenterol Clin Biol; 1996; 20(5 Pt 2):B80-88. PubMed ID: 8761126
    [No Abstract]   [Full Text] [Related]  

  • 30. Mutual Prodrugs of 5-Fluorouracil: From a Classic Chemotherapeutic Agent to Novel Potential Anticancer Drugs.
    Ciaffaglione V; Modica MN; Pittalà V; Romeo G; Salerno L; Intagliata S
    ChemMedChem; 2021 Dec; 16(23):3496-3512. PubMed ID: 34415107
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development of 5-Fluorouracil derivatives as anticancer agents.
    Pan X; Wang C; Wang F; Li P; Hu Z; Shan Y; Zhang J
    Curr Med Chem; 2011; 18(29):4538-56. PubMed ID: 21864282
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A review of analytical methods for the determination of 5-fluorouracil in biological matrices.
    Breda M; Barattè S
    Anal Bioanal Chem; 2010 Jun; 397(3):1191-201. PubMed ID: 20383700
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 5-fluorouracil-induced balanitis in a patient with oesophageal carcinoma.
    Tas F; Basaran M; Aydiner A; Eralp Y; Topuz E
    Clin Oncol (R Coll Radiol); 2001; 13(3):170-1. PubMed ID: 11527289
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 5-Fluorouracil: forty-plus and still ticking. A review of its preclinical and clinical development.
    Grem JL
    Invest New Drugs; 2000 Nov; 18(4):299-313. PubMed ID: 11081567
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The clinical applications of fluorouracil in ophthalmic practice.
    Abraham LM; Selva D; Casson R; Leibovitch I
    Drugs; 2007; 67(2):237-55. PubMed ID: 17284086
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antimetabolites.
    Chu E; Johnston PG; Takimoto CH; Politi PM; Grem JL; Chabner BA; Allegra CJ
    Cancer Chemother Biol Response Modif; 1993; 14():1-25. PubMed ID: 8312100
    [No Abstract]   [Full Text] [Related]  

  • 37. Can topical 5-fluorouracil be used as a viable treatment option for oral premalignant lesions and tumors?
    Routray S; Dikhit PS; Rajani BC; Khan MM
    Oral Oncol; 2019 Apr; 91():128. PubMed ID: 30777597
    [No Abstract]   [Full Text] [Related]  

  • 38. Antimetabolites.
    Johnston PG; Takimoto CH; Grem JL; Chabner BA; Allegra CJ; Chu E
    Cancer Chemother Biol Response Modif; 1996; 16():1-27. PubMed ID: 8639379
    [No Abstract]   [Full Text] [Related]  

  • 39. Potentiation by 2-deoxy-D-glucose tetraacetate of the antitumoral action of 5-fluorouracil in mice inoculated with L1210 ascites-producing cells.
    Olivares E; Kadiata MM; Malaisse WJ
    Oncol Rep; 1999; 6(6):1309-11. PubMed ID: 10523703
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of 5-FU.
    Wigmore PM; Mustafa S; El-Beltagy M; Lyons L; Umka J; Bennett G
    Adv Exp Med Biol; 2010; 678():157-64. PubMed ID: 20738018
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.